Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients

References

• Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670
   PubMed Web of Science ®Google Scholar
• Bernstein LR, Liotta LA. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 1994; 6:106-13; PMID:7515692; http://dx.doi.org/10.1097/00001622-199401000-00015
   PubMedGoogle Scholar
• Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13:555-62; PMID:11544023; http://dx.doi.org/10.1016/S0955-0674(00)00251-9
   PubMed Web of Science ®Google Scholar
• Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006; 281:17758-67; PMID:16632475; http://dx.doi.org/10.1074/jbc.M601812200
   PubMed Web of Science ®Google Scholar
• Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005; 24:1338-47; PMID:15592498; http://dx.doi.org/10.1038/sj.onc.1208337
   PubMed Web of Science ®Google Scholar
• Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer–clinical applications. Nat Rev Clin Oncol 2010; 7:693-701; PMID:20956980; http://dx.doi.org/10.1038/nrclinonc.2010.171
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29:1508-11; PMID:21422428; http://dx.doi.org/10.1200/JCO.2010.34.0026
   PubMed Web of Science ®Google Scholar
• Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol 2005; 23:1623-6; PMID:15755968; http://dx.doi.org/10.1200/JCO.2005.10.073
   PubMed Web of Science ®Google Scholar
• Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:2605-10; PMID:8219214.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-91; PMID:15317891; http://dx.doi.org/10.1056/NEJMoa040766
   PubMed Web of Science ®Google Scholar
• Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 2012; 130:1590-7; PMID:21469140; http://dx.doi.org/10.1002/ijc.26111
   PubMed Web of Science ®Google Scholar
• Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A, Di Leo A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118:523-30; PMID:19597704; http://dx.doi.org/10.1007/s10549-009-0461-7
   PubMed Web of Science ®Google Scholar
• Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A, Fehm T. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356-60; PMID:21605893; http://dx.doi.org/10.1016/j.ygyno.2011.04.039
   PubMed Web of Science ®Google Scholar
• Banys M, Krawczyk N, Becker S, Jakubowska J, Staebler A, Wallwiener D, Fehm T, Rothmund R. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012; 132:121-9; PMID:21562707; http://dx.doi.org/10.1007/s10549-011-1569-0
   PubMed Web of Science ®Google Scholar
• Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11:R59; PMID:19664291; http://dx.doi.org/10.1186/bcr2349
   PubMed Web of Science ®Google Scholar
• Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009; 118:455-68; PMID:19115104; http://dx.doi.org/10.1007/s10549-008-0290-0
   PubMed Web of Science ®Google Scholar
• Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010; 10:666; PMID:21129172; http://dx.doi.org/10.1186/1471-2407-10-666
   PubMed Web of Science ®Google Scholar
• Lauss M, Kriegner A, Vierlinger K, Visne I, Yildiz A, Dilaveroglu E, Noehammer C. Consensus genes of the literature to predict breast cancer recurrence. Breast Cancer Res Treat 2008; 110:235-44; PMID:17899371; http://dx.doi.org/10.1007/s10549-007-9716-3
   PubMed Web of Science ®Google Scholar
• Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72:1-22; PMID:9212216; http://dx.doi.org/10.1002/(SICI)1097-0215(19970703)72:1%3c1::AID-IJC1%3e3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• de Witte JH, Foekens JA, Brunner N, Heuvel JJ, van Tienoven T, Look MP, Klijn JG, Geurts-Moespot A, Grebenchtchikov N, Benraad T et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001; 85:85-92; PMID:11437407; http://dx.doi.org/10.1054/bjoc.2001.1867
   PubMed Web of Science ®Google Scholar
• Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001; 114:3387-96; PMID:11591826
   PubMed Web of Science ®Google Scholar
• Alexander RA, Prager GW, Mihaly-Bison J, Uhrin P, Sunzenauer S, Binder BR, Schutz GJ, Freissmuth M, Breuss JM. VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res 2012; 94:125-35; PMID:22287577; http://dx.doi.org/10.1093/cvr/cvs017
   PubMed Web of Science ®Google Scholar
• Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008; 36:160-7; PMID:18376307; http://dx.doi.org/10.1097/MPA.0b013e31815750f0
   PubMed Web of Science ®Google Scholar
• Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 2007; 282:35594-603; PMID:17923479; http://dx.doi.org/10.1074/jbc.M705867200
   PubMed Web of Science ®Google Scholar
• Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49:6008-14; PMID:2790815
   PubMed Web of Science ®Google Scholar
• Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M. Downregulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 2002; 21:5127-34; PMID:12140763; http://dx.doi.org/10.1038/sj.onc.1205657
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27; PMID:15585754; http://dx.doi.org/10.1200/JCO.2005.06.081
   PubMed Web of Science ®Google Scholar
• Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006; 66:46-51; PMID:16397214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3086
   PubMed Web of Science ®Google Scholar
• Dhillon N, Oki M, Szyjka SJ, Aparicio OM, Kamakaka RT. H2A.Z functions to regulate progression through the cell cycle. Mol Cell Biol 2006; 26:489-501; PMID:16382141; http://dx.doi.org/10.1128/MCB.26.2.489-501.2006
   PubMed Web of Science ®Google Scholar
• Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA, Shah PK, Liu J, Khramtsov A, Tretiakova MS et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008; 4:188; PMID:18414489; http://dx.doi.org/10.1038/msb.2008.25
   PubMed Web of Science ®Google Scholar
• Schweitzer KM, Drager AM, van der Valk P, Thijsen SF, Zevenbergen A, Theijsmeijer AP, van der Schoot CE, Langenhuijsen MM. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996; 148:165-75; PMID:8546203
   PubMed Web of Science ®Google Scholar
• Wagers AJ, Lowe JB, Kansas GS. An important role for the α 1,3 fucosyltransferase, FucT-VII, in leukocyte adhesion to E-selectin. Blood 1996; 88:2125-32; PMID:8822932
   PubMed Web of Science ®Google Scholar
• Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004; 64:5702-11; PMID:15313910; http://dx.doi.org/10.1158/0008-5472.CAN-04-0389
   PubMed Web of Science ®Google Scholar
• Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, Vallon-Christersson J, Jonsson G, Holm K, Lovgren K et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011; 11:418; PMID:21957977; http://dx.doi.org/10.1186/1471-2407-11-418
   PubMed Web of Science ®Google Scholar
• Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288:99-106; PMID:19619935; http://dx.doi.org/10.1016/j.canlet.2009.06.027
   PubMed Web of Science ®Google Scholar
• Calnan DR, Brunet A. The FoxO code. Oncogene 2008; 27:2276-88; PMID:18391970; http://dx.doi.org/10.1038/onc.2008.21
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30; PMID:16724053; http://dx.doi.org/10.1038/nature04869
   PubMed Web of Science ®Google Scholar
• Singh G, Chan AM. Post-translational modifications of PTEN and their potential therapeutic implications. Curr Cancer Drug Targets 2011; 11:536-47; PMID:21486223; http://dx.doi.org/10.2174/156800911795655930
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang Y, Zhu WG. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol 2011; 3:276-82; PMID:21669942; http://dx.doi.org/10.1093/jmcb/mjr013
   PubMed Web of Science ®Google Scholar
• Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012; 72 Suppl 1:28-36; PMID:22712795; http://dx.doi.org/10.2165/1163012-S0-000000000-00000
   PubMed Web of Science ®Google Scholar
• Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109-22; PMID:10923032; http://dx.doi.org/10.1002/1098-1004(200008)16:2%3c109::AID-HUMU3%3e3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-75; PMID:11687500; http://dx.doi.org/10.1146/annurev.cellbio.17.1.615
   PubMed Web of Science ®Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9:667-76; PMID:15505410; http://dx.doi.org/10.1023/B:APPT.0000045801.15585.dd
   PubMed Web of Science ®Google Scholar
• Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83:1688-95; PMID:11104567; http://dx.doi.org/10.1054/bjoc.2000.1522
   PubMed Web of Science ®Google Scholar
• Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger J et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011; 35:871-82; PMID:22195744; http://dx.doi.org/10.1016/j.immuni.2011.09.021
   PubMed Web of Science ®Google Scholar
• Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-44; PMID:19538929; http://dx.doi.org/10.1016/j.immuni.2009.04.014
   PubMed Web of Science ®Google Scholar
• Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
   PubMed Web of Science ®Google Scholar
• Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007; 7:449-60; PMID:17373897; http://dx.doi.org/10.1517/14712598.7.4.449
   PubMed Web of Science ®Google Scholar
• Zhang P, Maruyama T, Konkel JE, Abbatiello B, Zamarron B, Wang ZQ, Chen W. PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PloS One 2013; 8:e71590; PMID:23977081; http://dx.doi.org/10.1371/journal.pone.0071590
   PubMedGoogle Scholar
• Laurell H, Iacovoni JS, Abot A, Svec D, Maoret JJ, Arnal JF, Kubista M. Correction of RT-qPCR data for genomic DNA-derived signals with ValidPrime. Nucleic Acids Res 2012; 40:e51; PMID:22228834; http://dx.doi.org/10.1093/nar/gkr1259
   PubMedGoogle Scholar
• Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611-22; PMID:19246619; http://dx.doi.org/10.1373/clinchem.2008.112797
   PubMed Web of Science ®Google Scholar